Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002461 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

A Phase 2 study, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target

NCT00002461 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 35 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002461, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy to kill more cancer cells. PURPOSE: This phase II trial is studying giving high-dose chemotherapy followed by bone marrow or peripheral stem cell transplantation to see how well it works in treating patients with refractory Hodgkin's disease or non-Hodgkin's lymphoma.

Interventions

  • DRUG cisplatin
  • DRUG cyclophosphamide
  • DRUG carmustine
  • BIOLOGICAL filgrastim
  • BIOLOGICAL sargramostim

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 1988-04
Est. Completion 1991-07
Phase Phase 2

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT00002461

The ClinicalTrials.gov registry entry for NCT00002461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.

NCT00002461 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00002461 about?

NCT00002461 is a clinical study titled "Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy to kill more...

What is the current status of trial NCT00002461?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1988-04. Estimated completion is 1991-07.

What interventions are being tested in trial NCT00002461?

The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), carmustine (DRUG), filgrastim (BIOLOGICAL), sargramostim (BIOLOGICAL).

Who is sponsoring clinical trial NCT00002461?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.